Literature DB >> 23635046

Cardiovascular risks with azithromycin and other antibacterial drugs.

Andrew D Mosholder1, Justin Mathew, John J Alexander, Harry Smith, Sumathi Nambiar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23635046     DOI： 10.1056/NEJMp1302726

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  35 in total

1.  Should azithromycin no longer be considered a drug of choice for community-acquired pneumonia because of its potential to cause cardiovascular death?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2013-09

2.  [Medical therapy of heart and lung diseases. Effects on the respective other organ].

Authors:  S Möhlenkamp; G Weinreich; T Neumann; T Voshaar; H Teschler
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

3.  The cardiovascular safety of azithromycin.

Authors:  David N Juurlink
Journal:  CMAJ       Date:  2014-08-05       Impact factor: 8.262

Review 4.  Efficacy and safety of long-term antibiotics (macrolides) for the treatment of chronic rhinosinusitis.

Authors:  Anders Cervin; Ben Wallwork
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

5.  Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused?

Authors:  John R Giudicessi; Michael J Ackerman
Journal:  Cleve Clin J Med       Date:  2013-09       Impact factor: 2.321

Review 6.  Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Authors:  Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2014-12-10       Impact factor: 4.250

Review 7.  Pharmacological Management of Chronic Rhinosinusitis: Current and Evolving Treatments.

Authors:  Daniel M Beswick; Stacey T Gray; Timothy L Smith
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

Review 8.  Hemokinins and endokinins.

Authors:  N M Page
Journal:  Cell Mol Life Sci       Date:  2004-07       Impact factor: 9.261

9.  Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Ericka L Breden Crouse; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2013-10

Review 10.  Macrolide antibiotics and the risk of cardiac arrhythmias.

Authors:  Richard K Albert; Joseph L Schuller
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.